A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia

Completed · Phase 1 · Has a placebo group

Conditions studied: Mild Dyslipidemia

In brief

This Phase 1, double-blind (sponsor open) study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of ETC-1002 given to subjects with mild dyslipidemia.

Key facts

Study ID
NCT01105598
Run by
Esperion Therapeutics, Inc.
People needed
53
Starts
2010-04-20
Expected to finish
2010-10-02
Last updated by the study team
2019-03-28

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.